InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

Eye Drops for Red Eyes: LUMIFY significantly reduces redness to help reveal your eyes' natural radiance. From the eye care experts at Bausch and Lomb, LUMIFY works in 1 minute and lasts up to 8 ...

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price target ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of ... intraocular lenses, and eye surgery products, and made revenues of $4.15 billion last year.

Young nearsighted kids who wear bifocal contact lenses that slow uncoordinated eye growth do not lose the benefits of the treatment once they stop wearing the lenses, new research shows.

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration (iAMD) and diabetic retinal eye disease. Under the terms of the option ...

Vicks once again achieved the top monthly spot for TV impressions, while iSpot noted that pharma brands generated more year-over-year returns from sports and news cables compared to 2023.

Health scientists from the University of Virginia have found a previously unknown contributor to harmful blood vessel growth ...